1. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.
- Author
-
Tsimberidou, Apostolia, Alayli, Farah, Okrah, Kwame, Drakaki, Alexandra, Khalil, Danny, Kummar, Shivaani, Khan, Saad, Hodi, F, Oh, David, Cabanski, Christopher, Gautam, Shikha, Meier, Stefanie, Amouzgar, Meelad, Pfeiffer, Shannon, Kageyama, Robin, Yang, EnJun, Spasic, Marko, Tetzlaff, Michael, Foo, Wai, Hollmann, Travis, Li, Yanyun, Adamow, Matthew, Wong, Phillip, Moore, Jonni, Velichko, Sharlene, Chen, Richard, Kumar, Dinesh, Bucktrout, Samantha, Ibrahim, Ramy, Dugan, Ute, Salvador, Lisa, Hubbard-Lucey, Vanessa, ODonnell-Tormey, Jill, Santulli-Marotto, Sandra, Butterfield, Lisa, Da Silva, Diane, Fairchild, Justin, LaVallee, Theresa, Padrón, Lacey, and Sharma, Padmanee
- Subjects
Adult ,Aged ,Female ,Humans ,Male ,Middle Aged ,CD8-Positive T-Lymphocytes ,Drug Resistance ,Neoplasm ,Immune Checkpoint Inhibitors ,Ipilimumab ,Neoplasm Metastasis ,Neoplasms ,Nivolumab ,Tumor Microenvironment - Abstract
Identifying pan-tumor biomarkers that predict responses to immune checkpoint inhibitors (ICI) is critically needed. In the AMADEUS clinical trial (NCT03651271), patients with various advanced solid tumors were assessed for changes in intratumoral CD8 percentages and their response to ICI. Patients were grouped based on tumoral CD8 levels: those with CD8
- Published
- 2024